Results 141 to 150 of about 110,265 (199)

Devices as destination therapy

Cardiology Clinics, 2003
The use of circulatory support as destination therapy has been a goal for the treatment of endstage heart failure for several decades. Current investigations are evaluating several circulatory pumps with that particular objective. With continued modification of design, the current and future pumps will become more reliable and provide improved quality ...
Eugene L, Kukuy, Mehmet C, Oz, Eric A, Rose, Yoshifumi, Naka   +3 more
openaire   +2 more sources

Device Thrombosis During Destination Therapy

The American Journal of the Medical Sciences, 2016
Device thrombosis remains a complication of long-term mechanical circulatory support with HeartMate II.Retrospective analysis of patients who underwent destination therapy (DT) with HeartMate II from January 2010-December 2013 at Tulane University Medical Center.Eighteen HeartMate II were implanted for DT. Survival rates were 72.2% at 1 year and 37% at
Rohan, Samson, Indranee, Rajapreyar, Abhishek, Jaiswal, Brian, Payne, Mark, Cassidy, Michael, Weaver, Thierry H, Le Jemtel   +6 more
openaire   +2 more sources

Total artificial heart: Destination therapy

Cardiology Clinics, 2003
The AbioCor is a revolutionary device. It is the only device of its kind in the clinical world. The role of the AbioCor is to provide permanent replacement of the failing heart for patients who are not transplant candidates. The clinical trial has been successful in the majority (four of seven) of patients implanted thus far.
Louis E, Samuels, Robert, Dowling
openaire   +2 more sources

Destination Therapy with Ventricular Assist Devices

Cardiology, 2004
Despite extensive research and great strides over the past 40 years, the ideal permanent mechanical assist device remains elusive. The incidence of heart failure is increasing, and the number of heart transplants has remained constant. The HeartMate and Novacor are two pulsatile, long-term ventricular assist devices (VADs) commonly used as a bridge to ...
Jai, Raman, Valluvan, Jeevanadam
openaire   +2 more sources

Destination Therapy: Current Results and Future Promise

Seminars in Thoracic and Cardiovascular Surgery, 2008
The landmark Randomized Evaluation of Mechanical Assistance in the Treatment of Congestive Heart Failure (REMATCH) trial demonstrated that the implantation of left ventricular assist devices (LVADs) as an alternative to heart transplantation, or destination therapy (DT) is superior to any known medical therapy in patients with end-stage heart failure ...
Katherine, Lietz, Leslie W, Miller
openaire   +2 more sources

What If the Destination Is Transplant? Outcomes of Destination Therapy Patients Who Were Transplanted

ASAIO Journal, 2021
We sought to characterize patients who underwent heart transplant (HTx) following destination therapy (DT) implant in the combined ENDURANCE/ENDURANCE Supplemental Trials (DT/DT2). A post hoc analysis of the DT/DT2 trials was performed. Baseline characteristics and adverse events between the HTx and no-HTx cohorts were analyzed.
Pavan Atluri, Scott C. Silvestry, Jeffrey J. Teuteberg, Carmelo A. Milano, Craig H. Selzman, Jennifer A. Cowger   +5 more
openaire   +2 more sources

Ethics Guidelines for Destination Therapy

The Annals of Thoracic Surgery, 2006
The introduction of the left ventricular assist device as a destination therapy for patients with heart failure introduces several ethical issues. These issues are discussed to help destination therapy teams design ethically sound policies and procedures.
openaire   +2 more sources

Left Ventricular Assist Devices as Destination Therapy

AACN Clinical Issues: Advanced Practice in Acute and Critical Care, 2003
Although an estimated 16,500 Americans annually could benefit from a heart transplant, in 1999 only 2184 heart transplants were performed in the United States. These statistics emphasize the severity of the shortage of available hearts for transplantation.
Virginia Fidrocki, Mason, Annette Jakubisin, Konicki   +1 more
openaire   +2 more sources

Current Technology: Devices Available for Destination Therapy

Cardiology Clinics, 2011
Left ventricular assist device therapy as a destination therapy for end-stage heart failure has made a large leap with continuous flow devices. Continuous flow does not seem to have a detrimental effect on end-organ function, at least in the midterm. Various expected and unexpected complications have been reported associated with this technology.
Hiroo, Takayama, Jonathan A, Yang, Yoshifumi, Naka   +2 more
openaire   +2 more sources

DESTINATION THERAPY WITH DRIVE LESS TOTALARTIFICIAL HEARTS

INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, 2022
Around 70% of mechanical circulatory devices nd application as bridge to transplantation and 30% as destination devices, but shortage of donor organs forces up to 85% of these to enter the zone of destination devices. There is an urgent need to do away with drive lines as they contribute signicantly to morbidity and mortality with device implantation.
Pradeep Kumar Radhakrishnan, Himabindu A, Gayathri Ananyajyothi Ambat, Sachin Reddy, Sujatha Mohanty, Pulivarthi Nageshwar Rao, Sivakrishna Rao G V, Nagesh Kumar, Bisoi A K, Siva Prasad, Satyanarayana Murthy, Satyanarayana M R S, Ravishankar Ravishankar, Srinivas Srinivas, Valluvan Jeevanandam, Venugopal P   +15 more
openaire   +1 more source